BIENAIME JEAN JACQUES 4

What Happened Jean-Jacques Bienaime (Director) made three open-market purchases of Ascendis Pharma (ASND) stock on 2026-05-29, acquiring a total of 500 shares. The trades were: 200 shares at $223.76 ($44,752), 200 shares at $222.30 ($44,460), and 100 shares at $223.50 ($22,350), for a combined cash outlay of $111,562. These were purchases (Form 4 transaction code "P"), which are often viewed as a positive signal but do not guarantee future company performance.

Key Details

• Transaction date: 2026-05-29; Form 4 filed: 2026-06-01 (appears timely).
• Trades: 200 @ $223.76 ($44,752); 200 @ $222.30 ($44,460); 100 @ $223.50 ($22,350).
• Total acquired: 500 shares for $111,562.
• Shares owned after transaction: not disclosed in the filing.
• Footnotes/plans: no 10b5-1 plan, tax withholding, or other special footnotes reported in the filing.

Context These were outright purchases reported by a company director (code "P" = purchase). Director purchases can be informative for investors as they indicate the insider used personal funds to buy shares, but they should be considered alongside other company and market information. The filing appears to have been submitted within the standard SEC Form 4 reporting window.